ketoconazole has been researched along with Liver Neoplasms in 27 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease, but its effectiveness in Cushing's syndrome of ectopic or occult origin remains to be investigated." | 7.91 | Cabergoline in severe ectopic or occult Cushing's syndrome. ( Borson-Chazot, F; Ilie, MD; Raverot, G; Raverot, V; Tronc, F; Vasiljevic, A, 2019) |
| " The first was a case of ketoconazole-induced hepatitis, and the second was a case of hepatitis C-related liver cirrhosis with hepatocellular carcinoma." | 7.71 | Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases. ( Chang, FY; Huang, DF; Huang, YH; Huang, YS; Huo, TI; Lee, SD; Lin, CC; Wu, JC, 2001) |
| "Lacking a treatment for nonresectable hepatocellular carcinoma (HCC), we have utilized the androgen antagonist properties of ketoconazole in treating eight patients, seven men and one woman, with HCC, which, in view of a higher prevalence of HCC in men, seems to be androgen dependent." | 7.67 | Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. ( Gupta, S; Korula, J, 1988) |
| "Ketoconazole is a broad-spectrum antifungal agent, which has recently been characterized as a potential anticancer agent in several cancer types." | 5.51 | A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery. ( Chen, HN; Chen, Y; Huang, C; Wei, Y; Zhou, ZG, 2019) |
| "Cabergoline has been shown to have some effect in the treatment of moderate Cushing's disease, but its effectiveness in Cushing's syndrome of ectopic or occult origin remains to be investigated." | 3.91 | Cabergoline in severe ectopic or occult Cushing's syndrome. ( Borson-Chazot, F; Ilie, MD; Raverot, G; Raverot, V; Tronc, F; Vasiljevic, A, 2019) |
| "These results indicate that ketoconazole significantly reduced hepatic metastases from the human pancreatic carcinoma RWP-2 in the nude mouse model, and inhibited thromboxane B2 formation, potentiating a concomitant redirection of platelet endoperoxide metabolism into PGD2, PGE2, and 6-keto-F1a." | 3.71 | The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. ( Krambovitis, E; Tsatsakis, AM; Tzanakakis, GN; Vezeridis, MP, 2002) |
| " The first was a case of ketoconazole-induced hepatitis, and the second was a case of hepatitis C-related liver cirrhosis with hepatocellular carcinoma." | 3.71 | Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases. ( Chang, FY; Huang, DF; Huang, YH; Huang, YS; Huo, TI; Lee, SD; Lin, CC; Wu, JC, 2001) |
| "Lacking a treatment for nonresectable hepatocellular carcinoma (HCC), we have utilized the androgen antagonist properties of ketoconazole in treating eight patients, seven men and one woman, with HCC, which, in view of a higher prevalence of HCC in men, seems to be androgen dependent." | 3.67 | Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. ( Gupta, S; Korula, J, 1988) |
| "The effects of amphotericin B, ketoconazole, and adenine arabinoside on production of hepatitis B surface antigen (HBsAg) particles by the human hepatoma cell line PLC/PRF/5 were examined." | 3.67 | Inhibition of in vitro HBsAg production by amphotericin B and ketoconazole. ( Kessler, HA; Pottage, JC, 1985) |
| "Ixabepilone is a good CYP3A4 substrate in vitro; however, in humans, it is likely to be cleared by multiple mechanisms." | 2.73 | The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. ( André, F; Cohen, M; Cömezoglu, SN; Comprelli, A; Goel, S; Goldberg, G; Horwitz, SB; Humphreys, WG; Iacono, L; Jayabalan, D; Ly, VT; Mani, S; McDaid, H; Perrin, L; Xu, C; Zhang, D, 2008) |
| "Ketoconazole is a broad-spectrum antifungal agent, which has recently been characterized as a potential anticancer agent in several cancer types." | 1.51 | A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery. ( Chen, HN; Chen, Y; Huang, C; Wei, Y; Zhou, ZG, 2019) |
| "Ketoconazole (KTZ) has 2 chiral centers with the therapeutically active form being a racemic mixture of 2 cis-enantiomers, namely, (2R,4S)-(+)-KTZ and (2S,4R)-(-)-KTZ." | 1.43 | Ketoconazole Stereoisomers Differentially Induce Cytochrome P450 1A1 Between Human Hepatoma HepG2 and Mouse Hepatoma Hepa1c1c7 Cells. ( Anwar-Mohamed, A; Brocks, DR; El-Kadi, AO; El-Sherbeni, AA; Hamdy, DA; Korashy, HM, 2016) |
| "To predict the metabolic behavior and metabolism-based drug-drug interaction of gomisin G." | 1.42 | Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G. ( Chengqing, L; Chenming, N; Tao, L; Xiaoyang, L, 2015) |
| " Because loss of PXR maintains blood levels of paclitaxel upon chronic dosing, ketoconazole analogues may also serve to preserve paclitaxel blood levels on chronic dosing of drugs." | 1.34 | Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. ( Baker, SD; Huang, H; Kalpana, G; Li, H; Mani, S; Redinbo, MR; Sinz, M; Staudinger, J; Teotico, DG; Wang, H, 2007) |
| "Ketoconazole (KT) is a worldwide used oral antifungal agent with a broad spectrum of activity against both superficial and systemic mycosis." | 1.31 | Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity. ( Chen, CF; Chen, CH; Chen, LC; Ho, YS; Liang, YC; Lin, CH; Lin, JK; Lin, SY; Wang, YJ; Yu, CF, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (22.22) | 18.7374 |
| 1990's | 5 (18.52) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 2 |
| Chen, HN | 2 |
| Wang, K | 1 |
| Zhang, L | 1 |
| Huang, Z | 1 |
| Liu, J | 1 |
| Zhang, Z | 1 |
| Luo, M | 1 |
| Lei, Y | 1 |
| Peng, Y | 1 |
| Zhou, ZG | 2 |
| Wei, Y | 2 |
| Huang, C | 2 |
| Simó-Servat, A | 1 |
| Peiró, I | 1 |
| Villabona, C | 1 |
| Ilie, MD | 1 |
| Raverot, V | 1 |
| Tronc, F | 1 |
| Vasiljevic, A | 1 |
| Borson-Chazot, F | 1 |
| Raverot, G | 1 |
| Aggarwal, R | 1 |
| Halabi, S | 1 |
| Kelly, WK | 1 |
| George, D | 1 |
| Mahoney, JF | 1 |
| Millard, F | 1 |
| Stadler, WM | 1 |
| Morris, MJ | 1 |
| Kantoff, P | 1 |
| Monk, JP | 1 |
| Carducci, M | 1 |
| Small, EJ | 1 |
| Davi', MV | 1 |
| Salgarello, M | 1 |
| Francia, G | 1 |
| Xiaoyang, L | 1 |
| Chenming, N | 1 |
| Chengqing, L | 1 |
| Tao, L | 1 |
| Anwar-Mohamed, A | 1 |
| El-Sherbeni, AA | 1 |
| Hamdy, DA | 1 |
| Korashy, HM | 2 |
| Brocks, DR | 2 |
| El-Kadi, AO | 2 |
| La Rosa, S | 1 |
| Marando, A | 1 |
| Ghezzi, F | 1 |
| Colombo, P | 1 |
| Finzi, G | 1 |
| Capella, C | 1 |
| Wang, YJ | 1 |
| Yu, CF | 2 |
| Chen, LC | 1 |
| Chen, CH | 1 |
| Lin, JK | 2 |
| Liang, YC | 1 |
| Lin, CH | 1 |
| Lin, SY | 1 |
| Chen, CF | 1 |
| Ho, YS | 2 |
| Tzanakakis, GN | 3 |
| Krambovitis, E | 1 |
| Tsatsakis, AM | 1 |
| Vezeridis, MP | 3 |
| Trubetskoy, O | 1 |
| Marks, B | 1 |
| Zielinski, T | 1 |
| Yueh, MF | 1 |
| Raucy, J | 1 |
| Shayeganpour, A | 1 |
| Wang, H | 1 |
| Huang, H | 1 |
| Li, H | 1 |
| Teotico, DG | 1 |
| Sinz, M | 1 |
| Baker, SD | 1 |
| Staudinger, J | 1 |
| Kalpana, G | 1 |
| Redinbo, MR | 1 |
| Mani, S | 2 |
| Goel, S | 1 |
| Cohen, M | 1 |
| Cömezoglu, SN | 1 |
| Perrin, L | 1 |
| André, F | 1 |
| Jayabalan, D | 1 |
| Iacono, L | 1 |
| Comprelli, A | 1 |
| Ly, VT | 1 |
| Zhang, D | 1 |
| Xu, C | 1 |
| Humphreys, WG | 1 |
| McDaid, H | 1 |
| Goldberg, G | 1 |
| Horwitz, SB | 1 |
| Kolts, BE | 1 |
| Langfitt, M | 1 |
| Loose, DS | 1 |
| Stover, EP | 1 |
| Feldman, D | 1 |
| Parker, RA | 1 |
| Pearce, BC | 1 |
| Clark, RW | 1 |
| Gordon, DA | 1 |
| Wright, JJ | 1 |
| Tsai, PW | 1 |
| Liu, HL | 1 |
| Chen, RJ | 1 |
| Lin, CC | 1 |
| Wu, JC | 1 |
| Huang, DF | 1 |
| Huang, YS | 1 |
| Huang, YH | 1 |
| Huo, TI | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Kornely, E | 1 |
| Schlaghecke, R | 1 |
| Horster, FA | 1 |
| Agarwal, KC | 2 |
| Veronikis, DK | 1 |
| Gupta, S | 1 |
| Korula, J | 1 |
| Pottage, JC | 1 |
| Kessler, HA | 1 |
| Kempen, HJ | 1 |
| van Son, K | 1 |
| Cohen, LH | 1 |
| Griffioen, M | 1 |
| Verboom, H | 1 |
| Havekes, L | 1 |
| Contreras, P | 1 |
| Altieri, E | 1 |
| Liberman, C | 1 |
| Gac, A | 1 |
| Rojas, A | 1 |
| Ibarra, A | 1 |
| Ravanal, M | 1 |
| Serón-Ferré, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone In Patients With Advanced Cancer[NCT00096317] | Phase 1 | 29 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ketoconazole and Liver Neoplasms
| Article | Year |
|---|---|
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Com | 2013 |
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Computational Biology; Cytochrome P-450 CYP3A | 2008 |
25 other studies available for ketoconazole and Liver Neoplasms
| Article | Year |
|---|---|
Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclooxygenase 2; Cytochrome P-450 CYP3A Inh | 2019 |
Corticotropin secreting pancreatic neuroendocrine tumour, a therapeutic management challenge. A presentation of 2 cases.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Chromogranins; Combined Modality Therapy; Embol | 2019 |
A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery.
Topics: Autophagy; Carcinoma, Hepatocellular; Cyclooxygenase 2; Humans; Ketoconazole; Liver Neoplasms; Mitop | 2019 |
Cabergoline in severe ectopic or occult Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; Adult; Aged; Cabergoline; Carcinoid Tumor; Cushing Syndrome; Dopamine Agonis | 2019 |
Positive (68)Ga-DOTATOC-PET/CT after cortisol level control during ketoconazole treatment in a patient with liver metastases from a pancreatic neuroendocrine tumor and ectopic Cushing syndrome.
Topics: Cushing Syndrome; Gallium Radioisotopes; Humans; Hydrocortisone; Ketoconazole; Liver Neoplasms; Male | 2015 |
Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G.
Topics: Antineoplastic Agents; Cyclooctanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diox | 2015 |
Ketoconazole Stereoisomers Differentially Induce Cytochrome P450 1A1 Between Human Hepatoma HepG2 and Mouse Hepatoma Hepa1c1c7 Cells.
Topics: Animals; Antifungal Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; He | 2016 |
Cushing's syndrome due to a pancreatic neuroendocrine tumor metastatic to the ovaries: a clinicopathological description of a case.
Topics: ACTH Syndrome, Ectopic; Adult; Carcinoma, Neuroendocrine; Cushing Syndrome; Fatal Outcome; Female; H | 2011 |
Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity.
Topics: Animals; Apoptosis; Baculoviridae; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Cytochrome P-4 | 2002 |
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Animals; Antineoplastic Agents; Dinoprostone; Humans; | 2002 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytoch | 2005 |
Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines.
Topics: Animals; Antifungal Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; | 2007 |
Activated pregnenolone X-receptor is a target for ketoconazole and its analogs.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Genes, Reporter; Humans; Ketoconazole; L | 2007 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 1984 |
Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells.
Topics: Animals; Antifungal Agents; Carcinoma, Hepatocellular; Cells, Cultured; Clotrimazole; Dexamethasone; | 1983 |
Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Acetates; Acetic Acid; Androstenes; Animals; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell L | 1993 |
Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Hepato | 1998 |
Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases.
Topics: Antifungal Agents; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Female; Hepati | 2001 |
Palliative therapy of an ectopic Cushing's syndrome due to a metastatic carcinoid tumor.
Topics: ACTH Syndrome, Ectopic; Adult; Carcinoid Tumor; Combined Modality Therapy; Cushing Syndrome; Dose-Re | 1991 |
Effects of antiplatelet agents alone or in combinations on platelet aggregation and on liver metastases from a human pancreatic adenocarcinoma in the nude mouse.
Topics: Adenocarcinoma; Animals; Colforsin; Drug Interactions; Humans; Indomethacin; Ketoconazole; Liver Neo | 1991 |
Inhibition of hepatic metastasis from a human pancreatic adenocarcinoma (RWP-2) in the nude mouse by prostacyclin, forskolin, and ketoconazole.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colforsin; Epoprostenol; Hu | 1990 |
Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Androgen Antagonists; Carcinoma, Hepatocellular; Female; Humans; Ke | 1988 |
Inhibition of in vitro HBsAg production by amphotericin B and ketoconazole.
Topics: Amphotericin B; Antigens, Neoplasm; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line; Depressi | 1985 |
Effect of ketoconazole on cholesterol synthesis and on HMG-CoA reductase and LDL-receptor activities in Hep G2 cells.
Topics: Carcinoma, Hepatocellular; Cell Line; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 1987 |
Adrenal rest tumor of the liver causing Cushing's syndrome: treatment with ketoconazole preceding an apparent surgical cure.
Topics: 11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; Adrenal Rest Tumor; Adult; Cushing Syndrome; F | 1985 |